Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Latest From Hemispherx

  • Hemispherx News 04

Prostate Cancer News Today Provides an Ampligen Upate

July 9th, 2019|

Prostate Cancer News Today Provides an Ampligen Update We recently announced that the Roswell Park Comprehensive Cancer Center had received FDA authorization to proceed with its Phase 2 study using our lead [...]

  • Hemispherx News 02

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019|

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

Latest From Hemispherx

  • Hemispherx News 04

Prostate Cancer News Today Provides an Ampligen Upate

July 9th, 2019|

Prostate Cancer News Today Provides an Ampligen Update We recently announced that the Roswell Park Comprehensive Cancer Center had received FDA authorization to proceed with its Phase 2 study using our lead [...]

  • Hemispherx News 02

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019|

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

Want More Info?

Click below for all our contact information

Let’s Talk